
|Articles|February 24, 2015
- NSCLC (Issue 6)
- Volume 6
- Issue 1
Diagnostic Platforms for Lung Cancer
Author(s)Maria E. Arcila, MD
Maria E. Arcila, MD, acting director, Diagnostic Molecular Pathology Laboratory, Memorial Sloan Kettering Cancer Center, discusses diagnostic platforms for lung cancer.
Advertisement
Maria E. Arcila, MD, acting director, Diagnostic Molecular Pathology Laboratory, Memorial Sloan Kettering Cancer Center, discusses diagnostic platforms for lung cancer.
<<<
Articles in this issue
over 10 years ago
Nanovesicles as Targeted Therapy for Lung Cancerover 10 years ago
Prior Cancer Diagnosis Not Viable Exclusion From Lung Cancer Trialsover 10 years ago
Liquid Biopsy Use in NSCLC Clinical Practice on the Horizonover 10 years ago
Lung Cancer Screening: Implementing the New Protocolover 10 years ago
Maintenance Therapies for Patients with Non-Small Cell Lung Cancerover 10 years ago
Challenges Oncologists Face in Treating Lung Cancerover 10 years ago
Potential Modulator of NSCLC Metastasis IdentifiedAdvertisement
Latest CME
Advertisement
Advertisement






































